CN110327373A - Maggot infusing drugs in wine product is for treating the application in diabetes - Google Patents
Maggot infusing drugs in wine product is for treating the application in diabetes Download PDFInfo
- Publication number
- CN110327373A CN110327373A CN201910642598.7A CN201910642598A CN110327373A CN 110327373 A CN110327373 A CN 110327373A CN 201910642598 A CN201910642598 A CN 201910642598A CN 110327373 A CN110327373 A CN 110327373A
- Authority
- CN
- China
- Prior art keywords
- maggot
- wine
- infusing drugs
- composition
- diabetes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 77
- 229940079593 drug Drugs 0.000 title claims abstract description 66
- 206010012601 diabetes mellitus Diseases 0.000 title claims abstract description 38
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims abstract description 98
- 102000004877 Insulin Human genes 0.000 claims abstract description 49
- 108090001061 Insulin Proteins 0.000 claims abstract description 49
- 229940125396 insulin Drugs 0.000 claims abstract description 49
- 239000000203 mixture Substances 0.000 claims abstract description 34
- 238000002360 preparation method Methods 0.000 claims abstract description 10
- KFSLWBXXFJQRDL-UHFFFAOYSA-N Peracetic acid Chemical compound CC(=O)OO KFSLWBXXFJQRDL-UHFFFAOYSA-N 0.000 claims description 18
- 239000000843 powder Substances 0.000 claims description 17
- 238000000034 method Methods 0.000 claims description 14
- 238000002791 soaking Methods 0.000 claims description 14
- 238000004659 sterilization and disinfection Methods 0.000 claims description 10
- PQLVXDKIJBQVDF-UHFFFAOYSA-N acetic acid;hydrate Chemical compound O.CC(O)=O PQLVXDKIJBQVDF-UHFFFAOYSA-N 0.000 claims description 9
- 239000000645 desinfectant Substances 0.000 claims description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- 238000002560 therapeutic procedure Methods 0.000 claims description 7
- 239000002775 capsule Substances 0.000 claims description 6
- 230000036541 health Effects 0.000 claims description 6
- 238000007789 sealing Methods 0.000 claims description 6
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 claims description 5
- 229940033663 thimerosal Drugs 0.000 claims description 5
- 230000001476 alcoholic effect Effects 0.000 claims description 4
- 235000013305 food Nutrition 0.000 claims description 4
- 150000001875 compounds Chemical class 0.000 claims description 3
- 239000002552 dosage form Substances 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 3
- 229940100688 oral solution Drugs 0.000 claims description 3
- 239000006187 pill Substances 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims description 3
- 239000008103 glucose Substances 0.000 abstract description 34
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract description 31
- 206010022489 Insulin Resistance Diseases 0.000 abstract description 27
- 210000004369 blood Anatomy 0.000 abstract description 25
- 239000008280 blood Substances 0.000 abstract description 25
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract description 16
- 238000012360 testing method Methods 0.000 abstract description 5
- PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 abstract description 4
- 101000976075 Homo sapiens Insulin Proteins 0.000 abstract description 3
- 238000002651 drug therapy Methods 0.000 abstract description 2
- 230000007774 longterm Effects 0.000 abstract description 2
- 230000003578 releasing effect Effects 0.000 description 17
- 230000000694 effects Effects 0.000 description 10
- 238000007410 oral glucose tolerance test Methods 0.000 description 9
- 230000007423 decrease Effects 0.000 description 6
- 230000007812 deficiency Effects 0.000 description 6
- 210000004153 islets of langerhan Anatomy 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 229940088597 hormone Drugs 0.000 description 4
- 239000005556 hormone Substances 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 102000051325 Glucagon Human genes 0.000 description 3
- 108060003199 Glucagon Proteins 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 235000013339 cereals Nutrition 0.000 description 3
- 238000002648 combination therapy Methods 0.000 description 3
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 3
- 229960004666 glucagon Drugs 0.000 description 3
- 201000001421 hyperglycemia Diseases 0.000 description 3
- 230000003914 insulin secretion Effects 0.000 description 3
- 235000012054 meals Nutrition 0.000 description 3
- 230000035922 thirst Effects 0.000 description 3
- 208000015817 Infant Nutrition disease Diseases 0.000 description 2
- 240000000249 Morus alba Species 0.000 description 2
- 235000008708 Morus alba Nutrition 0.000 description 2
- 240000005373 Panax quinquefolius Species 0.000 description 2
- 235000003140 Panax quinquefolius Nutrition 0.000 description 2
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000010835 comparative analysis Methods 0.000 description 2
- 230000001079 digestive effect Effects 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 244000000053 intestinal parasite Species 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 241000257161 Calliphoridae Species 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 241000202815 Chrysomya megacephala Species 0.000 description 1
- 101001012217 Conus geographus Con-Ins G3 Proteins 0.000 description 1
- 101001012221 Conus tulipa Con-Ins T3 Proteins 0.000 description 1
- 244000247747 Coptis groenlandica Species 0.000 description 1
- 235000002991 Coptis groenlandica Nutrition 0.000 description 1
- 210000004128 D cell Anatomy 0.000 description 1
- 206010012218 Delirium Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 102000017011 Glycated Hemoglobin A Human genes 0.000 description 1
- 108010014663 Glycated Hemoglobin A Proteins 0.000 description 1
- 206010018473 Glycosuria Diseases 0.000 description 1
- 102000018997 Growth Hormone Human genes 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 241000545744 Hirudinea Species 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 241000234479 Narcissus Species 0.000 description 1
- 235000002789 Panax ginseng Nutrition 0.000 description 1
- 241000219780 Pueraria Species 0.000 description 1
- 241000405911 Rehmannia glutinosa Species 0.000 description 1
- 244000299790 Rheum rhabarbarum Species 0.000 description 1
- 235000009411 Rheum rhabarbarum Nutrition 0.000 description 1
- 240000006079 Schisandra chinensis Species 0.000 description 1
- 235000008422 Schisandra chinensis Nutrition 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000002141 anti-parasite Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000003096 antiparasitic agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000002641 glycemic effect Effects 0.000 description 1
- 239000004519 grease Substances 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 229910052602 gypsum Inorganic materials 0.000 description 1
- 239000010440 gypsum Substances 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000003910 polypeptide antibiotic agent Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 229940026314 red yeast rice Drugs 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000010415 tropism Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 229940126673 western medicines Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
- A61K35/64—Insects, e.g. bees, wasps or fleas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Insects & Arthropods (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Emergency Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Nutrition Science (AREA)
- Polymers & Plastics (AREA)
- Animal Husbandry (AREA)
- Food Science & Technology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
The invention discloses a kind of maggot infusing drugs in wine products for treating the application in diabetes, and the maggot infusing drugs in wine product is used to prepare the composition for the treatment of diabetes, or preparation adjusts the composition of insulin level.It has been investigated that, maggot especially maggot infusing drugs in wine product, which can effectively eliminate, reverses human insulin to resist and improve human insulin sensitivity, discovery patient takes after maggot infusing drugs in wine product treats in carrying out compliance test result, insulin resistance and insulin sensitivity can be made to obtain that blood glucose level is significantly reversed to become normally, and blood glucose is steady in a long-term after deactivating all drug therapies.It is the discovery great for the first time of Chinese TCM Treatment of Diabetes.
Description
Technical field
The invention belongs to food, pharmaceutical technology field, and in particular to a kind of maggot infusing drugs in wine product is for treating glycosuria
Application in disease.
Background technique
Insulin is a kind of protein hormone, and internal insulin is by islet β cell.
Islet cells is divided into following several according to the function of its secreting hormone:
1. B cell (β cell), accounts for about the 60%~80% of islet cells, excreting insulin, insulin can reduce blood
Sugar.
2. A cell (α cell) accounts for about the 24%~40% of islet cells, glucagon is secreted, glucagon acts on same pancreas
Island element is on the contrary, can increase blood glucose.
3. D cell accounts for about the 6%~15% of islet cells sum, secretes growth hormone inhibits hormones.
Diabetic, due to the various pathogenic factors such as virus infection, gene, autoimmunity, pathologic, physiologic master
If due to insulin active relative or absolute deficiency and glucagon activity are opposite or it is absolutely excessive caused by namely B and A it is thin
Caused by the bilateral hormone dysfunction of born of the same parents.Diabetes are one group of metabolic diseases characterized by hyperglycemia.Hyperglycemia be then due to
Defect of insulin secretion or its biological effect are impaired, or both have concurrently and cause.Long-standing hyperglycemia when diabetes causes each
Kind tissue, especially eye, kidney, heart, blood vessel, the chronic lesion of nerve, dysfunction etc..The whole world does not have any method at present
Human insulin function is enabled to be restored and reverse in treatment diabetes mellitus.
Maggot is Calliphoridae insect chrysomyia megacephala or the drying larva body of other nearly edge insects, Chinese medicine maggot alias paddy
Worm, narcissus, Luo Xianzi, the worm nature and flavor are salty, sweet, cold, and channel tropism spleen, stomach, chemical component mainly contain protein, lysozyme, amino
Acid, grease, toxicity very little play the role of clearing heat and detoxicating, consumer product dredge stasis.Recording in Compendium of Material Medica can be used for treating children's infantile malnutrition due to digestive disturbances or intestinalparasites
Product, infantile malnutrition due to digestive disturbances or intestinalparasites sore, febrile delirium, fulminant dysentery such as spit at the diseases.To which the effective component in maggot not only has antibacterial, antiviral work
With also having the effects that anti parasitic, anti-oxidant, anti-aging, antitumor.
In the prior art, a kind of drug for treating diabetes is disclosed in patent CN107375825A, by dietary alkali, mouse
Woman, ant, maggot, mulberry leaf, radices trichosanthis, gypsum, radix rehmanniae recen, Rehmannia glutinosa, fructus lycii, mulberry fruit, gentianae macrophyllae, red ginseng, American Ginseng, Pueraria lobota
Root etc. is prepared according to a certain weight ratio, and drug of the present invention is warm with clearing damp, helping digestion is stagnant, tonifying kidney and benefiting sperm, relaxing tendons and activating collaterals, expelling pathogenic factors from muscles and skin
Heat-clearing promotes the production of body fluid to quench thirst, the function of beneficial lung yin, the clear fire of deficiency type, and diabetes are quick, good effect for treating, and do not recur.The wherein group
It closes the maggot that object uses and plays the role of heat-clearing, disappear stagnant, be ministerial drug.
A kind of drug for treating hyperlipidemia with diabetes is described in patent CN102335241A, by following parts by weight
Bulk pharmaceutical chemicals be made: 6-10 parts of raw rhubarb, 3-10 parts of leech, 10-30 parts of maggot, 10-30 parts of red yeast rice, 10-15 parts of Schisandra chinensis.
Its lasting medicine, good effect.Wherein the composition use maggot also with its it is salty-cold enter taste pass through, disappear stagnant heat-clearing, with
And effect for reducing fat is obviously to add.
A kind of drug for being used to prepare treatment type II diabetes is described in patent CN108404088A, by following parts by weight
Raw material composition: 30-80 parts of rhizoma zingiberis, 150-220 parts of the coptis, 150-220 parts of radix scutellariae, 20-45 parts of American Ginseng, radices trichosanthis 150-220
Part and maggot 150-220 parts.Turbid, supplementing qi and nourishing yin Chinese medicine curative principle drops by heat-clearing, for treating caused by deficiency of both qi and yin
The card such as thirst and liking drink, fatigue and weakness, deficiency of QI with disinclination to talk, there is thirst and liking drink caused by deficiency of both qi and yin, tired especially suitable for treatment
The type II diabetes of the diseases such as idle out of strength, deficiency of QI with disinclination to talk.
Although as it can be seen that only contain maggot in above-mentioned three parts of patents, maggot wherein the effect of be only heat-clearing
Disappear stagnant, and do not record maggot individually and have the function of treat diabetes with and restore insulin resistance and raising insulin is quick
The effect of sense.
Moreover, the drug (including newest oral medicine) or method of all treatment diabetes published at present are indirect
Improved with insulin resistance and insulin sensitivity as main target, but using blood glucose improvement as main target diabetic's pancreas
Insulin resistance and insulin sensitivity can not restore and reverse to be the generally acknowledged problem in our times medical field diabetes field, and institute
There is the final conclusion of textbook.
Summary of the invention
The object of the present invention is to provide a kind of maggot infusing drugs in wine products for treating the application in diabetes, specially five
Application of the paddy worm infusing drugs in wine product in the composition of preparation treatment diabetes or the composition of adjusting insulin level.
The purpose of the present invention is what is be achieved through the following technical solutions:
In a first aspect, the present invention provides a kind of maggot infusing drugs in wine products in the composition for being used to prepare treatment diabetes
Application.
Second aspect, the present invention provides a kind of maggot infusing drugs in wine products in the composition that preparation adjusts insulin level
Application.
Preferably, the composition includes any one of drug, health care product, food.
Preferably, the maggot infusing drugs in wine product preparation method the following steps are included:
B1, the full worm of the maggot of collection is cleaned, is washed away, the dirty removal surface is clean；
B2, the full worm of step B1 treated maggot is subjected to soaking disinfection, then rinses, drains；
B3, the full worm of the maggot after draining is put into wine, is sealed up for safekeeping；
B4, the full worm of the maggot after sealing up for safekeeping is taken out, carry out Cryogenic Ultrafine crush to get.
Preferably, in step B2, the thimerosal that the soaking disinfection uses is the mixing of water and peracetic acid disinfectant stoste
Object；The more preferable soaking time is 10 minutes, and the volume ratio of water and peracetic acid disinfectant stoste is 1:400.
Preferably, in step B3, the weight ratio of the maggot full worm and wine are as follows: 0.2: 0.8~0.4:0.6；Institute
State seal up for safekeeping the time be 2 months or more.
Preferably, the pure grain wine that the wine is 55 °~70 ° of alcoholic strength.
Preferably, dosage form made of the maggot includes capsule, tablet, pill, powder, compound granule, health care
Any one of wine, oral solution or freeze-dried powder.
The third aspect, the present invention also provides a kind of methods based on aforementioned composition treatment diabetes, including following step
It is rapid:
After detecting, according to the extent of diabetes, 1-6 course of therapy is carried out, each course for the treatment of is three months；It is described
The treatment method of each course for the treatment of are as follows: take the composition comprising maggot infusing drugs in wine product, maggot in the composition taken daily
The dosage of infusing drugs in wine product is 1500mg-15g.
Fourth aspect, the present invention also provides a kind of methods for adjusting insulin level based on aforementioned composition, including with
Lower step:
After detecting, according to the extent of diabetes, 1-6 course of therapy is carried out, each course for the treatment of is three months；It is described
The treatment method of each course for the treatment of are as follows: take the composition comprising maggot infusing drugs in wine product, maggot in the composition taken daily
The dosage of infusing drugs in wine product is 1500mg-15g.
Compared with prior art, the present invention have it is following the utility model has the advantages that
Maggot infusing drugs in wine product of the invention is a kind of natural product, and maggot infusing drugs in wine product effective component is maggot
Full worm, modern medicine study prove: containing protein in maggot, fat, chitosan, contain antibacterial peptide and a variety of amino acid.
It include all effective components of the full worm of maggot in maggot freeze-dried powder of the invention, maggot extract is mainly with fat
Acid and/or protein, polypeptide, amino acid etc..It has been investigated that maggot infusing drugs in wine product can more efficient elimination human pancreatic islet
Human insulin sensitivity is resisted and improved to element, and discovery patient takes maggot infusing drugs in wine product and treats in carrying out compliance test result
Afterwards, diabetic's insulin resistance can be substantially eliminated and greatly improve insulin sensitivity some patientss insulin level and be restored to
The level of normal person, and maggot infusing drugs in wine product does not have the drug resistance and its toxic side effect of clinically common chemotherapeutic.
Further investigation of the present inventor to maggot infusing drugs in wine products therapies diabetes target user, through front and back glucose tolerance
(OGTT) measurement analysis compare, found on medical significance and have found evidence proof take human body pair after maggot infusing drugs in wine product
Insulin resistance and insulin sensitivity are all effective in cure, and blood glucose is steady in a long-term after deactivating all drug therapies.It is Chinese traditional Chinese medicine
The discovery great for the first time for treating diabetes.
For the present invention by maggot product patent medicine, carrying is convenient to take, and clinical effective rate reaches 98%, and patient is controlled by conventional
Withdrawal observation longest is up to 5 years or more after treatment, and stable disease, blood glucose are normal so far.
Detailed description of the invention
Upon reading the detailed description of non-limiting embodiments with reference to the following drawings, other feature of the invention,
Objects and advantages will become more apparent upon:
Fig. 1 is the glucose tolerance curve of present invention verifying example one；
Fig. 2 is the insulin releasing curve of present invention verifying example one；
Fig. 3 is the glucose tolerance curve of present invention verifying example two；
Fig. 4 is the insulin releasing curve of present invention verifying example two；
The insulin releasing curve of Fig. 5 present invention verifying example three；
Fig. 6 is the glucose tolerance curve of present invention verifying example four；
Fig. 7 is the insulin releasing curve of present invention verifying example four.
Specific embodiment
The present invention is described in detail combined with specific embodiments below.Following embodiment will be helpful to the technology of this field
Personnel further understand the present invention, but the invention is not limited in any way.It should be pointed out that the ordinary skill of this field
For personnel, without departing from the inventive concept of the premise, various modifications and improvements can be made.These belong to the present invention
Protection scope.
Following embodiment provides a kind of maggot infusing drugs in wine product answering in the composition for being used to prepare treatment diabetes
With.
Following embodiment provides a kind of maggot infusing drugs in wine product answering in the composition that preparation adjusts insulin level
With.
The composition includes any one of drug, health care product, food.
The preparation method of the maggot infusing drugs in wine product the following steps are included:
B1, the full worm of the maggot of collection is cleaned, is washed away, the dirty removal surface is clean；
B2, the full worm of step B1 treated maggot is subjected to soaking disinfection, then rinses, drains；
B3, the full worm of the maggot after draining is put into wine, is sealed up for safekeeping；
B4, the full worm of the maggot after sealing up for safekeeping is taken out, carry out Cryogenic Ultrafine crush to get.
In step B2, the thimerosal that the soaking disinfection uses is described for the mixture of water and peracetic acid disinfectant stoste
Soaking time is 10 minutes；The volume ratio of more preferable water and peracetic acid disinfectant stoste is 1:400.
In step B3, the weight ratio of the maggot full worm and wine are as follows: 0.2: 0.8~0.4:0.6；It is described when sealing up for safekeeping
Between be 2 months or more.
The pure grain wine that the wine is 55 °~70 ° of alcoholic strength.
Dosage form made of the maggot infusing drugs in wine product includes capsule, tablet, pill, powder, compound granule, health care
Any one of wine, oral solution or freeze-dried powder.
Following embodiment additionally provides a kind of method treated diabetes based on aforementioned composition, adjust insulin level,
The following steps are included:
After detecting, according to the extent of diabetes, 1-6 course of therapy is carried out, each course for the treatment of is three months；It is described
The treatment method of each course for the treatment of are as follows: take the composition comprising maggot infusing drugs in wine product, maggot in the composition taken daily
The dosage of infusing drugs in wine product is 1500mg-15g.
Embodiment 1
Present embodiments provide a kind of maggot process for preparation of dry powder, comprising the following steps:
A1, the full worm of the maggot of collection is cleaned, is washed away, the dirty removal surface is clean；
A2, the full worm of step A1 treated maggot is subjected to soaking disinfection, then rinses, drains；
A3, the full worm of the maggot after draining is subjected to cryogenic freezing, be then freeze-dried to moisture content lower than 10wt%；
A4, the full worm of maggot after freeze-drying is subjected to Cryogenic Ultrafine crushing to get maggot dry powder.
In step A2, the thimerosal that the soaking disinfection uses is described for the mixture of water and peracetic acid disinfectant stoste
Soaking time is 10 minutes；The volume ratio of water and peracetic acid disinfectant stoste is 1:400.
In step A3, the temperature of the cryogenic freezing is -20-50 DEG C, cooling time is for 24 hours.
Embodiment 2
Present embodiments provide a kind of preparation method of maggot infusing drugs in wine product, comprising the following steps:
B1, the full worm of the maggot of collection is cleaned, is washed away, the dirty removal surface is clean；
B2, the full worm of step B1 treated maggot is subjected to soaking disinfection, then rinses, drains；
B3, the full worm of the maggot after draining is put into wine, is sealed up for safekeeping；
B4, the full worm of the maggot after sealing up for safekeeping is taken out, carry out Cryogenic Ultrafine crush to get.
In step B2, the thimerosal that the soaking disinfection uses is described for the mixture of water and peracetic acid disinfectant stoste
Soaking time is 10 minutes；The volume ratio of water and peracetic acid disinfectant stoste is 1:400.
In step B3, the weight ratio of the maggot full worm and wine are as follows: 0.2: 0.8~0.4:0.6；It is described when sealing up for safekeeping
Between be 2 months or more；The pure grain wine that the wine is 55 °~70 ° of alcoholic strength.
Compliance test result:
Maggot dry powder and maggot infusing drugs in wine product prepared by the embodiment of the present invention 1 and 2 are subjected to treatment diabetes, adjusted
The compliance test result of insulin level provides specific treatment verifying example further below.
Verify example one, using maggot freeze-dried powder and maggot infusing drugs in wine combination therapy
Shen * * pure Chinese medicine treats Shanghai director of the Institute
Therapeutic scheme are as follows: three times a day, maggot dry powder capsule prepared by each 1500mg example 1 is taken before the meal；Sleep preceding clothes
The maggot infusing drugs in wine product prepared with 2000mg embodiment 2.
Comparative analysis before and after OGTT: the secondary interval OGTT of patient 60 days, practical medication 45 days.The inspection of Shanghai Sixth Man people hospital
Observing and predicting announcement, the results are shown in Table 1.
Table 1
It is analyzed from glucose tolerance curve (Fig. 1):
1, fasting blood-glucose declines 0.63mmol/L, and 180 minutes blood glucose is declined by 8.0mmol/L causes 5.3mmol/L to return just
Often.
2, resistance to sugared peak value reverses Forward, is caused 60 minutes by initial Forwards in 120 minutes.
Insulin releasing curve (Fig. 2) analysis:
1, fasting insulin resists symptom and is improved:
A: fasting insulin release decline 48.43%, blood glucose has dropped 0.63mmol/L
B:180 minutes insulin releases decline 44.42%, and blood glucose returns normal person's standard.
Prove that insulin resistance is repaired.
2,60 minutes insulin releasings and empty stomach multiple, which are seen, increases to 9.22 times of (normal value 5-10 by initial 3.52 times
Times), insulin, which releases peak value, increases to 11.16 times (5-10 times of normal values) by initial 5.01 times.
Prove that insulin sensitivity is improved.
3, insulin peak release rises to 103.2 μ IU/mL by 91.46 μ IU/mL before taking medicine, and increases by 11.38%.
Above analytical proof patient insulin resistance and insulin sensitivity after maggot conditioning of the invention is two-way significant
Improve, so that its insulin level is restored to normal person's level.
Prove that patient is insulin resistance and the two-way damage of insulin sensitivity by the result.
Verify example two, using maggot freeze-dried powder and maggot infusing drugs in wine combination therapy
Patient: it name: XX gender: the male age: makes a definite diagnosis within 55 years old and suffers from diabetes 5 years
Metformin Extended-release Tablets 0.5g 2 before treating, withdraw all western medicines in 19 days.
Therapeutic scheme are as follows: three times a day, maggot dry powder capsule prepared by each 1500mg example 1 is taken before the meal；Sleep preceding clothes
The maggot infusing drugs in wine product prepared with 2000mg embodiment 2.
The secondary OGTT report in front and back: (interval 120 days) the second the People's Hospital of Wuxi City, Jiangsu Province examining report result such as table 2
It is shown.
Table 2
| Project | 0 minute | 30 minutes | 60 minutes | 120 minutes | 180 minutes | |
| Before medication | Blood glucose value mmol/L 0 | 8.41 | 13.00 | 16.72 | 17.96 | 11.87 |
| Insulin μ IU/mL 0 | 10.85 | 45.00 | 80.16 | 38.31 | 21.13 | |
| After medication | Blood glucose value mmol/L 1 | 6.52 | 11.83 | 14.08 | 12.66 | 4.75 |
| Insulin μ IU/mL 1 | 6.72 | 24.18 | 35.32 | 47.81 | 10.07 |
It is analyzed from glucose tolerance curve (Fig. 3):
1, fasting blood-glucose drops to 6.52mmol/L by 8.41mmol/L and returns normally.
2,30 minutes blood glucose drops to 11.83mmol/L by 13.00mmol/L.
3,60 minutes blood glucose drops to 14.08mmol/L by 16.72mmol/L.
4,120 minutes blood glucose drops to 12.66mmol/L by 17.96mmol/L.
5,180 minutes blood glucose drops to 4.75mmol/L by 11.87mmol/L and returns normally.
6, resistance to sugared peak value reverses Forward, is moved forward to 60 minutes by initial 120 minutes.
It is analyzed from insulin releasing curve (Fig. 4):
1, fasting insulin declines 38.06% blood glucose and returns normally.
2,30 minutes insulin releasing 46.27% blood glucose of decline has dropped 1.17mmol/L.
3,60 minutes insulin releasing decline 55.94.27% blood glucose has dropped 2.64mmol/L.
4,180 minutes insulin releasing 52.34% blood glucose of decline has dropped 5.30mmol/L.
5, it is also reduced from each point analysis insulin of the upper insulin releasing blood glucose that declines to a great extent and illustrates insulin resistance
Significantly repaired.Prove that patient is damaged based on insulin resistance by the result.
Verify example three, using maggot freeze-dried powder and maggot infusing drugs in wine combination therapy
Patient's name: Lyu's XX gender: the male age: start within 36 years old 2019/3/14 treatment and withdraw all Western medicine in 71 days.
Therapeutic scheme are as follows: three times a day, maggot dry powder capsule prepared by each 1500mg example 1 is taken before the meal；Sleep preceding clothes
The maggot infusing drugs in wine product prepared with 2000mg embodiment 2.
The secondary OGTT report in front and back: interval 96 days, HbAlc drops to 5.8 by 6.7, and insulin level is as shown in table 3.
Table 3
| Project | 0 minute | 30 minutes | 60 minutes | 120 minutes | 180 minutes | |
| Before medication | Insulin μ IU/mL 0 | 5.00 | 8.00 | 12.60 | 23.30 | 15.60 |
| After medication | Insulin μ IU/mL 1 | 3.43 | 10.01 | 27.74 | 26.22 | 21.97 |
It is analyzed from insulin releasing curve (Fig. 5):
1. patient takes medicine, 96 days insulin releasing integral areas are significantly increased.
2. the ratio between peak insulin and fasting insulin increase to 8.09 times by 4.66 times, increase by 3.43 times.
3. insulin releasing peak value was moved forward to 60 minutes by 120 minutes.
4. peak insulin increases to 27.74 μ IU/mL by 23.3 μ IU/mL, increase by 19.06%.
Prove that patient is damaged based on insulin sensitivity by the result.
Maggot infusing drugs in wine products therapies are applied alone in verifying example four
Name king's * * gender: female's age: suffer within 65 years old diabetes 10 years
Therapeutic scheme are as follows: secondary daily, maggot infusing drugs in wine product prepared by each 2000mg embodiment 2.
Comparative analysis before and after OGTT: the secondary interval OGTT of patient 156 days, practical medication 156 days.Testing result such as 4 institute of table
Show.
Table 4
It is analyzed from glucose tolerance curve (Fig. 6):
1, fasting blood-glucose drops to 7.00mmol/L by 7.45mmol/L.
2,60 minutes blood glucose drops to 13.54mmol/L by 15.13mmol/L.
3,120 minutes blood glucose drops to 8.20mmol/L by 17.25mmol/L and returns normally.
4, resistance to sugared peak value reverses Forward, is moved forward to 60 minutes by initial 120 minutes, meets the special card of the resistance to sugar of normal person.
It is analyzed from insulin releasing curve (Fig. 7):
1, fasting insulin declines 30.16% blood glucose and declines 0.45mmol/L.
2,120 minutes insulin releasing 74.08% blood glucose of decline has dropped 9.05mmol/L.
It is substantially eliminated according to 2 points of proof insulin resistances of 1-2 or more
3,0 minute insulin releasing of Insulin 3 and rehabilitation are than rising to 2.62 times by initial 1.67 times.
It is also improved according to the above analytical proof insulin sensitivity.
Maggot infusing drugs in wine product made from 2000mg embodiment 2 is equivalent to maggot dry powder made from 500mg embodiment 1
Dosage, from analysis patient is applied alone maggot infusing drugs in wine product usage amount far below above three in verifying example four and effect is equally bright
It is aobvious, so maggot infusing drugs in wine product is applied alone and is actually better than maggot pulvis in diabetic's effect.
It is measured and is analyzed through front and back OGTT by the therapeutic effect to above four patients, using maggot treatment diabetes tool
There is safety, long-acting, whole body improves advantage.Elimination insulin resistance is had found on medical significance, promotes insulin normal secretions
Evidence.
Diabetic is controlled through treating after a period of time using maggot at present, the survey of secondary OGTT before and after comparison patient
It is scheduled on and is medically proven patients with insulin resistance and is able to repair and the promotion of insulin sensitivity, controlled stopping all drugs
The glycemic control of (2-5) patient can all reach excellent after treatment, and glycosylated hemoglobin rebounds without an example so far less than 6.3.
There are many concrete application approach of the present invention, the above is only a preferred embodiment of the present invention.More than it should be pointed out that
Embodiment is merely to illustrate the present invention, and the protection scope being not intended to restrict the invention.For the common skill of the art
For art personnel, without departing from the principle of the present invention, several improvement can also be made, these improvement also should be regarded as this hair
Bright protection scope.
Claims (10)
1. a kind of application of maggot infusing drugs in wine product in the composition for being used to prepare treatment diabetes.
2. a kind of application of maggot infusing drugs in wine product in the composition that preparation adjusts insulin level.
3. application according to claim 1 or 2, which is characterized in that the composition includes drug, health care product, in food
It is any.
4. application according to claim 1 or 2, which is characterized in that dosage form made of the maggot infusing drugs in wine product includes
Any one of capsule, tablet, pill, powder, compound granule, health liquor, oral solution or freeze-dried powder.
5. application according to claim 1 or 2, which is characterized in that the preparation step of the maggot infusing drugs in wine product includes:
B1, the full worm of the maggot of collection is cleaned, is washed away, the dirty removal surface is clean；
B2, the full worm of step B1 treated maggot is subjected to soaking disinfection, then rinses, drains；
B3, the full worm of the maggot after draining is put into wine, is sealed up for safekeeping；
B4, the full worm of the maggot after sealing up for safekeeping is taken out, carry out Cryogenic Ultrafine crush to get.
6. application according to claim 5, which is characterized in that in step B2, thimerosal that the soaking disinfection uses for
The mixture of water and peracetic acid disinfectant stoste.
7. application according to claim 5, which is characterized in that in step B3, the parts by weight of the maggot full worm and wine
Ratio are as follows: 0.2: 0.8~0.4:0.6；It is described seal up for safekeeping the time be 2 months or more.
8. application according to claim 5, which is characterized in that in step B3, the wine is 55 °~70 ° of alcoholic strength pure
Grain wine.
9. a kind of method based on composition described in claim 1 treatment diabetes, which comprises the following steps:
After detecting, according to the extent of diabetes, 1-6 course of therapy is carried out, each course for the treatment of is three months；It is described each
The treatment method of the course for the treatment of are as follows: take the composition comprising maggot infusing drugs in wine product, maggot infusing drugs in wine in the composition taken daily
The dosage of product is 1500mg-15g.
10. a kind of method for adjusting insulin level based on composition described in claim 1, which is characterized in that including following
Step:
After detecting, according to the extent of diabetes, 1-6 course of therapy is carried out, each course for the treatment of is three months；It is described each
The treatment method of the course for the treatment of are as follows: take the composition comprising maggot infusing drugs in wine product, maggot infusing drugs in wine in the composition taken daily
The dosage of product is 1500mg-15g.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910642598.7A CN110327373B (en) | 2019-07-16 | 2019-07-16 | Application of maggot wine-soaked product in treatment of diabetes |
| PCT/CN2019/104318 WO2021007934A1 (en) | 2019-07-16 | 2019-09-04 | Application of liquor product with soaked lucilia sericata for treating diabetes |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910642598.7A CN110327373B (en) | 2019-07-16 | 2019-07-16 | Application of maggot wine-soaked product in treatment of diabetes |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN110327373A true CN110327373A (en) | 2019-10-15 |
| CN110327373B CN110327373B (en) | 2021-03-16 |
Family
ID=68145485
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910642598.7A Active CN110327373B (en) | 2019-07-16 | 2019-07-16 | Application of maggot wine-soaked product in treatment of diabetes |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN110327373B (en) |
| WO (1) | WO2021007934A1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021007933A1 (en) * | 2019-07-16 | 2021-01-21 | 华祥荣 | Application of maggots in treatment of diabetes |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102335241A (en) * | 2011-10-12 | 2012-02-01 | 郭聚忠 | Medicine for treating diabetes mellitus associated with hyperlipemia, and preparation method thereof |
-
2019
- 2019-07-16 CN CN201910642598.7A patent/CN110327373B/en active Active
- 2019-09-04 WO PCT/CN2019/104318 patent/WO2021007934A1/en active Application Filing
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102335241A (en) * | 2011-10-12 | 2012-02-01 | 郭聚忠 | Medicine for treating diabetes mellitus associated with hyperlipemia, and preparation method thereof |
Non-Patent Citations (2)
| Title |
|---|
| 聂春丽等: "中西医结合治疗2 型糖尿病胰岛素抵抗的Meta 分析", 《世界中医药》 * |
| 肖永庆等: "《中药炮制学》", 30 September 2016 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021007933A1 (en) * | 2019-07-16 | 2021-01-21 | 华祥荣 | Application of maggots in treatment of diabetes |
| US11096970B2 (en) | 2019-07-16 | 2021-08-24 | Xiangrong Hua | Preparation and application of grain worm for treating diabetes |
| US12059440B2 (en) | 2019-07-16 | 2024-08-13 | Xiangrong Hua | Preparation and application of grain worm for treating diabetes |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2021007934A1 (en) | 2021-01-21 |
| CN110327373B (en) | 2021-03-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103566350B (en) | A kind of pharmaceutical composition with hypoglycemic effect | |
| CN105250723B (en) | A kind of drug for treating diabetes | |
| CN102205095A (en) | Medicinal composition with auxiliary blood sugar reducing effect | |
| CN104083640B (en) | Traditional Chinese medicinal composition for treating diabetes mellitus and preparation method thereof | |
| CN107551192A (en) | A kind of Traditional Chinese medicine compound composition with treatment CKD and preparation method and application | |
| CN110327373A (en) | Maggot infusing drugs in wine product is for treating the application in diabetes | |
| CN110302213A (en) | Maggot is for treating the application in diabetes | |
| CN103191295A (en) | Medicine for treating diabetes mellitus | |
| CN106822583A (en) | A kind of regulation blood pressure, blood fat, Chinese medicine composition of blood sugar and preparation method thereof | |
| CN106822231A (en) | Biological bacterium solution with function of blood sugar reduction and preparation method thereof | |
| CN101007137A (en) | 'Qimailing' oral liquid and its preparation method | |
| CN109498731A (en) | A kind of tonifying speen and tonifying kidney tune sugar-pill and preparation method thereof for treating diabetes B Pishenqixu syndrome | |
| CN102150716B (en) | Medicinal tea with function of treating diabetes and preparation method thereof | |
| CN107048104A (en) | A kind of astaxanthin beverage for auxiliary treatment diabetes | |
| CN113041300A (en) | Prescription for treating diabetes and its application | |
| CN105663772B (en) | A kind of drug for treating diabetes | |
| CN104784472A (en) | Traditional Chinese medicine composition for decreasing blood sugar to treat diabetes | |
| CN106729304B (en) | A kind of Chinese medicine for mitigating fasting or side reaction of dieting and preparation method thereof | |
| CN109758559A (en) | A kind of Chinese medicine composition and its preparation method and application for treating chronic fatigue syndrome | |
| CN104288229B (en) | The Chinese medicine finish and its production technology of a kind of Transdermal absorption treatment diabetes B | |
| CN115779046B (en) | Traditional Chinese medicine composition, traditional Chinese medicine preparation and application for preventing and treating diabetes | |
| CN105770394A (en) | Diabetes treatment medicine | |
| CN105535195A (en) | Traditional Chinese medicine preparation for treating diabetes and preparation method and application thereof | |
| CN109820075A (en) | A kind of drink tea improving diabetes patient | |
| CN116549520A (en) | Qi-blood tonifying, lung heat clearing and cough relieving traditional Chinese medicine formula, traditional Chinese medicine liquid and traditional Chinese medicine preparation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |